Key result
Supportive therapy rapidly resolves sepsis-like symptoms in a neonate with recombinant PeV-A5 infection.
Why the study?
Although PeV-A3 has a known association with severe disease, severe cases of PeV-A5 infection have recently been reported.
Case Report (n=1)
PeV-A5 infection can cause severe sepsis-like symptoms in neonates, potentially driven by genetic recombination with PeV-A3.
Encourages PeV-A5 testing in neonatal sepsis-like illness with rash; leaves open genotype-specific virulence and requires larger surveillance studies.[[1]](https://www.sciencedirect.com/science/article/pii/S1341321X26000802)[[2]](https://pmc.ncbi.nlm.nih.
Parechovirus A (PeV-A) is a significant cause of sepsis-like illnesses in neonates and infants. Although PeV-A3 has a known association with severe diseases, severe cases of PeV-A5 infection have recently been reported. We present herein a case of PeV-A5 infection in a 23-day-old neonate who presented with sepsis-like symptoms, including fever, irritability, abdominal distension, and a reticular rash. An erythematous rash developed and spread from the trunk to the extremities after the patient's admission. Blood cultures were negative, and the patient's symptoms rapidly improved with supportive therapy. Polymerase chain reaction testing of pharyngeal and rectal swabs confirmed PeV-A5 infection, as well as the presence of PeV-A5 in the serum during the acute phase. PeV-A5 RNA was undetectable in serum at follow-up testing, whereas stool specimens showed higher detection sensitivity, indicating that the time from symptom onset and specimen selection influence diagnostic accuracy. Whole-genome analysis suggested a recombinant PeV-A5 strain with structural protein regions similar to those of PeV-A5 and nonstructural regions similar to those of PeV-A3. This genomic feature may explain the patient's clinical presentation resembling that of a PeV-A3 infection. PeV-A5 may cause sepsis-like symptoms in early infancy, the pathogenicity of which may be affected by genetic recombination. Further case studies are required to elucidate the clinical features and pathogenicity of PeV-A5 infection.
No takes yet. Share an insight, caveat, or question.
Ishiwata et al. (2026) conducted a case report in Parechovirus A Type 5 (PeV-A5) infection (n=1). Supportive therapy was evaluated. A 23-day-old neonate with sepsis-like symptoms was confirmed to have a recombinant Parechovirus A Type 5 (PeV-A5) infection that rapidly improved with supportive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: